BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
  • Interviews
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
  • AI in Bio
  • Outsourced R&D
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence

Roman Kasianov

Director at BiopharmaTrend    

Covers AI in drug discovery, digital pathology, and translational R&D, editor of "Where Tech Meets Bio"; oversees company profiles, partnerships, and core operations at BiopharmaTrend.


Recent articles from Roman

The Virtual Cell Tracker: Who’s Building Them, What Works, Where the Money Goes

Nov. 4, 2026      Business Intelligence
The Virtual Cell Tracker: Who’s Building Them, What Works, Where the Money Goes

Latest changes · October 30, 2026

  • Biohub’s data push hit $1.8B with DOE, NIH, Google DeepMind, Isomorphic and Meta joining; commercial funders get a one-year head start on the data.
  • One of the first big-pharma licenses …

Is “Rescuing Failed Drugs with AI” a Category Now?

May 22, 2026      Business Intelligence
Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed...

Update (October 2026): Five months after this piece was first published, Biossil raised another $153 million (C$216 million) at a $1 billion valuation, this …

Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in Line

Sept. 29, 2026      Business Intelligence
Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in Line

Recently, Iambic Therapeutics has filed to go public on Nasdaq under the ticker IAM, adding another closely watched name to a biotech IPO market that has begun to reopen after one of its weakest years in recent memory.

Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic

April 9, 2026      News
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic

Boston-based Life Biosciences, co-founded by David Sinclair, has closed an $80 million Series D financing to fund its first-in-human clinical program and extend operations into 2027. The capital is allocated primarily to a Phase 1 trial of ER-100 …

Everyone is Launching AI Agents. What's Being Deployed?

April 4, 2026      Business Intelligence
Everyone is Launching AI Agents. What's Being Deployed?

A deep dive on the next cycle of biopharma's AI buildout

Last year's "growing buzz around AI agents" that we surveyed has since grown into a full avalanche of infrastructure commitments, partnerships, and agent launches across nearly every corner …

$1 Billion-Backed Xaira Launches Its First Virtual Cell Model

March 17, 2026      News
$1 Billion-Backed Xaira Launches Its First Virtual Cell Model

Xaira Therapeutics has announced X-Cell, the company's first virtual cell model. It is a 4.9-billion-parameter diffusion language model designed to predict how cells respond to genetic perturbations, including in biological contexts not seen during training. X-Cell is trained on X-Atlas/Pisces, …

Recursion Logs Fifth Sanofi Milestone, Says Joint Immunology-Oncology Portfolio Has Potential for 15 Programs

Feb. 25, 2026      News
Recursion Logs Fifth Sanofi Milestone, Says Joint Immunology-Oncology Portfolio Has Potential for 15 Programs

Salt Lake City clinical-stage AI drug developer Recursion reported a fifth progress-based milestone in its collaboration with Sanofi, bringing total payments under that partnership to $134 million to date. The company also disclosed $754 million in cash and cash equivalents …

OpenAI Backs Ultrasound-Based Brain-Computer Interface Startup With $252M Seed Round

Jan. 16, 2026      News
OpenAI Backs Ultrasound-Based Brain-Computer Interface Startup With $252M Seed Round

Merge Labs has emerged from stealth with $252 million in funding to develop non-implantable brain–computer interfaces that use ultrasound and molecular approaches rather than electrodes. The company is cofounded by Sam Altman and is positioned at the intersection of neurotechnology, …

Insilico Deploys its Chemistry Foundation Model on Microsoft Discovery Platform

Jan. 15, 2026      News
Insilico Deploys its Chemistry Foundation Model on Microsoft Discovery Platform

Insilico Medicine reported the deployment of its Nach01 multimodal foundation model on Microsoft Discovery, Microsoft’s Azure-based platform for AI-driven research and development. The demonstration illustrates how third-party foundation models can be orchestrated within a single enterprise environment to support end-to-end …

Novo Nordisk Foundation Commits €736M to Scale European Life Sciences

Jan. 15, 2026      News
Novo Nordisk Foundation Commits €736M to Scale European Life Sciences

The Novo Nordisk Foundation has committed up to €736 million (~$856 million) to Copenhagen-based BioInnovation Institute in a nine-year funding program aimed at expanding early-stage life sciences and deep tech activity across Europe. The capital is earmarked to increase the …

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Outsourced R&D
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar
  • Sponsored Content

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.

Sign in or create an account